Work Group Interpretation and Next Steps

Mary Choi, MD, MPH
Viral Special Pathogens Branch
Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices

October 23, 2019

WG Interpretation of MERCK Data

- Encouraging evidence for effectiveness in prevention of EVD when administered in an outbreak setting using a ring-vaccination strategy
- Acceptable safety profile
- Arthritis was an adverse event in a subset of study participants (Europe, U.S.)
- No known immune correlate for protection
- EBOV-GP specific IgG antibodies can persist in vaccinees up to 24 months

Vaccine Safety Discussion Points

- Virus dissemination and replication (skin, joints) can occur and persist for up to 2-3 weeks after vaccination
  - Seeding of rVSV-ZEBOV into joints as demonstrated by detection of rVSV DNA in synovial fluid
  - Replicating rVSV-ZEBOV recovered from skin vesicles (culture)
- Pathophysiology of chimeric rVSV-ZEBOV vaccine may include features attributable to both its VSV and ZEBOV glycoprotein components; may play a role in the development of arthralgia/arthritis

Agnandji et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe NEJM 2016

Anticipated Next Steps

- GRADE and Evidence to Recommendations Framework
- Presentation of policy options
- Vote on policy options, pending vaccine licensure, February 2020
  - Potential for an emergency meeting in the event the vaccine is not licensed by February 2020

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.